New York, March 2, 2026, 18:43 EST — After-hours
UnitedHealth Group Inc ended after-hours trade on Monday up 0.5%, closing at $294.93. Shares moved between $290.71 and $295.26 over the session, with roughly 8.1 million changing hands.
UNH, often viewed as a benchmark among U.S. managed-care names, remains in focus as investors weigh ongoing worries over Medicare Advantage rates and medical expenses heading into this quarter. The filings posted Monday keep those concerns front and center, offering a glimpse at just how much leeway the company is seeking in terms of funding.
UnitedHealth on Monday put in a Form S-3 shelf registration, covering debt, preferred and common stock, warrants, plus guarantees. This setup allows the company to quickly offer securities in the future by filing a prospectus supplement at the time of sale.
An 8-K filing outlined some shuffling in the accounting ranks: Dennis Stankiewicz, currently corporate controller, is stepping up to chief accounting officer effective March 2. Tom Roos, who’s held that CAO role for years, is shifting over to become CFO at Optum Insight. According to the filing, Stankiewicz’s new base salary comes in at $550,000, with a targeted annual cash bonus set at 85% of that.
UnitedHealth’s 2025 annual report, filed Monday, listed 907,675,839 shares outstanding as of Feb. 20. Optum Rx reported pharmaceutical spend at $188 billion for 2025, while Optum Insight’s backlog sat at roughly $31.1 billion—$18.3 billion of that expected to convert within a year. UnitedHealthcare closed out the year with 8.4 million Medicare Advantage members, but warned that number is likely to shrink in 2026 due to funding pressures.
Health care stocks lost ground as the filings landed. The Health Care Select Sector SPDR ETF dropped roughly 1%. Elevance Health tumbled close to 8%, Humana edged down 1.7%. The S&P 500 proxy SPY barely moved.
Shelves don’t mean much until activated; investors typically wait for that prospectus supplement to see deal details—size, price, the works. For managed care, sharper Medicare audits or softer rate hikes could eat into margins before insurers get a chance to slash costs or hike premiums.
The risk resurfaced Monday when the U.S. Centers for Medicare & Medicaid Services announced plans to halt enrollment in Elevance’s Medicare Advantage prescription drug plans as of March 31 if problems aren’t addressed. Elevance responded, saying it would look over the CMS letter and open a dialogue, and has until March 10 to push back. Barclays analyst Andrew Mok described the action as “a negative regulatory signal that adds uncertainty” as CMS broadens its risk-adjustment audits—insurers get higher payments for taking on sicker patients, based on diagnosis data. Reuters
